A new ophthalmic technique could treat a rare condition that has been fatal for patients

An Australian team is developing a new ocular technique that could treat the rare form of macular degeneration, known as ocular myelopathy.

The research team, led by Dr Andrew McNeill from the University of Melbourne, said the technique could be used to treat the condition, which is rare in Australia.

Dr McNeill said macular myelopathic degeneration was caused by a mutation in a gene that was responsible for making the protein that forms the outer layer of the lens.

“The mutation causes the outer layers of the cells to become fused together,” he said.

“If that happens, the inner cells are unable to fuse, the lens starts to crack and the outer lens is damaged.”

When that happens you lose the ability to see.

“It’s a very exciting and very exciting time for ophthalmologists and ophthalpathologists, who are already doing very exciting things to treat macular lesions, including lasers, and this is just the first step. “

We’re trying to reduce the amount of damage, so we can then use the repaired macular lens to help restore sight,” he explained.

Dr McKay said he hoped the device could eventually be used by surgeons to treat a variety of diseases. “

The next step is to develop a way of doing it that can be used in humans.”

Dr McKay said he hoped the device could eventually be used by surgeons to treat a variety of diseases.

He said the technology would be used at hospitals in the United States, Europe, Asia, Africa, and the Middle East.

Dr McKay, who also worked with Dr Mitchell of the National Ocular Institute, said he was particularly excited by the potential of this technique for treating macular injury and other degenerative eye diseases.

“This technique is an important advancement for our understanding of the macular pathway,” he told ABC News.

“I think we can start to see this technology be used as a first-line treatment for patients with degenerative macular diseases and other eye conditions.”

Dr Mitchell said the team had been working on developing the technology for more than a year and hoped to start clinical trials within a year.

“There is a lot of promise in the technology,” he added.

“This technology is going to help in the early stages of this technology, so there are a lot more opportunities for it to be developed and used in the clinical setting.”